| |
|
|
|
|
|
|
|||
|
Blood, 15 December 2006, Vol. 108, No. 13, pp. 4009-4017. Prepublished online as a Blood First Edition Paper on August 29, 2006; DOI 10.1182/blood-2006-04-015024.
GENE THERAPY Modification of antigen-encoding RNA increases stability, translational efficacy, and T-cell stimulatory capacity of dendritic cellsFrom the Department of Internal Medicine III, Division of Experimental and Translational Oncology, Johannes-Gutenberg University, Mainz, Germany.
Adoptive transfer of dendritic cells (DCs) transfected with in vitrotranscribed, RNA-encoding, tumor-associated antigens has recently entered clinical testing as a promising approach for cancer immunotherapy. However, pharmacokinetic exploration of RNA as a potential drug compound and a key aspect of clinical development is still pending. While investigating the impact of different structural modifications of RNA molecules on the kinetics of the encoded protein in DCs, we identified components located 3' of the coding region that contributed to a higher transcript stability and translational efficiency. With the use of quantitative reverse transcriptionpolymerase chain reaction (RT-PCR) and eGFP variants to measure transcript amounts and protein yield, we showed that a poly(A) tail measuring 120 nucleotides compared with a shorter one, an unmasked poly(A) tail with a free 3' end rather than one extended with unrelated nucleotides, and 2 sequential
This article has been cited by other articles:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| |||||||||||
| Copyright © 2006 by American Society of Hematology Online ISSN: 1528-0020 | |||||||||||